title: [The measurement of 153Sm-EDTMP bone uptake rate and its relationship with therapeutic effect].
abstract: OBJECTIVE
  To evaluate the measurement of 153Sm-EDTMP Bone uptake rate with whole-body scintigraphy and analyze the relationship between bone uptake rate and therapeutic effect.
  
  
  METHODS
  66 patients with bony metastases were examined with whole-body scintigraphy 10 minutes and 6 hours after the administration of 153Sm-EDTMP, and then bone uptake rate was calculated.
  
  
  RESULTS
  The bone uptake rate in 66 patients ranged from 31.9% to 86.6%, (mean 56.0%). The patients with higher bone uptake rate had better overall therapeutic effect. According to the bone uptake rate calculated by whole-body scintigraphy, the therapy activity administered within the limit of bone marrow absorbed dose of 1400 mGy in these patients was 1.40-2.27GBq (mean 1.90 GBq).
  
  
  CONCLUSIONS
  The present authors have developed a whole-body scintigraphic technique which is simple and reliable in calculating prospectively a safe and effective dose of 153Sm-EDTMP for palliating the patient's painful bone metastases without myelotoxicity.
authors.affiliation: Department of Nuclear Medicine, First Affiliated Hospital, WCUMS, Chengdu 610041, China.
authors.forename: L
authors.initials: L
authors.lastname: Li
authors.forename: Z
authors.initials: Z
authors.lastname: Liang
authors.forename: H
authors.initials: H
authors.lastname: Deng
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: X
authors.initials: X
authors.lastname: Zhang
authors.forename: X
authors.initials: X
authors.lastname: Yang
mesh_terms: D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary*; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000378:metabolism*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D011877:Radionuclide Imaging
chemical_list: D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; C061972:samarium Sm-153 lexidronam